4nm8 › Citations

A common solution to group 2 influenza virus neutralization.

Friesen RH, Lee PS, Stoop EJ, Hoffman RM, Ekiert DC, Bhabha G, Yu W, Juraszek J, Koudstaal W, Jongeneelen M, Korse HJ, Ophorst C, Brinkman-van der Linden EC, Throsby M, Kwakkenbos MJ, Bakker AQ, Beaumont T, Spits H, Kwaks T, Vogels R, Ward AB, Goudsmit J, Wilson IA
Proc Natl Acad Sci U S A 111 445-50 (2014)
Cited: 131 times
EuropePMC logo PMID: 24335589

Abstract

The discovery and characterization of broadly neutralizing antibodies (bnAbs) against influenza viruses have raised hopes for the development of monoclonal antibody (mAb)-based immunotherapy and the design of universal influenza vaccines. Only one human bnAb (CR8020) specifically recognizing group 2 influenza A viruses has been previously characterized that binds to a highly conserved epitope at the base of the hemagglutinin (HA) stem and has neutralizing activity against H3, H7, and H10 viruses. Here, we report a second group 2 bnAb, CR8043, which was derived from a different germ-line gene encoding a highly divergent amino acid sequence. CR8043 has in vitro neutralizing activity against H3 and H10 viruses and protects mice against challenge with a lethal dose of H3N2 and H7N7 viruses. The crystal structure and EM reconstructions of the CR8043-H3 HA complex revealed that CR8043 binds to a site similar to the CR8020 epitope but uses an alternative angle of approach and a distinct set of interactions. The identification of another antibody against the group 2 stem epitope suggests that this conserved site of vulnerability has great potential for design of therapeutics and vaccines.

Reviews - 4nm8 mentioned but not cited (7)

  1. A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. Wu NC, Wilson IA. J Mol Biol 429 2694-2709 (2017)
  2. Tackling influenza with broadly neutralizing antibodies. Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A. Curr Opin Virol 24 60-69 (2017)
  3. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Lee PS, Wilson IA. Curr Top Microbiol Immunol 386 323-341 (2015)
  4. Antibody specific epitope prediction-emergence of a new paradigm. Sela-Culang I, Ofran Y, Peters B. Curr Opin Virol 11 98-102 (2015)
  5. A molecular roadmap to the plant immune system. Bentham AR, De la Concepcion JC, Mukhi N, Zdrzałek R, Draeger M, Gorenkin D, Hughes RK, Banfield MJ. J Biol Chem 295 14916-14935 (2020)
  6. Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy. Tung Yep A, Takeuchi Y, Engelhardt OG, Hufton SE. Biomolecules 11 407 (2021)
  7. Analysis of the conserved protective epitopes of hemagglutinin on influenza A viruses. Jiao C, Wang B, Chen P, Jiang Y, Liu J. Front Immunol 14 1086297 (2023)

Articles - 4nm8 mentioned but not cited (8)

  1. A common solution to group 2 influenza virus neutralization. Friesen RH, Lee PS, Stoop EJ, Hoffman RM, Ekiert DC, Bhabha G, Yu W, Juraszek J, Koudstaal W, Jongeneelen M, Korse HJ, Ophorst C, Brinkman-van der Linden EC, Throsby M, Kwakkenbos MJ, Bakker AQ, Beaumont T, Spits H, Kwaks T, Vogels R, Ward AB, Goudsmit J, Wilson IA. Proc Natl Acad Sci U S A 111 445-450 (2014)
  2. Quadrivalent influenza nanoparticle vaccines induce broad protection. Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M. Nature 592 623-628 (2021)
  3. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Guthmiller JJ, Han J, Utset HA, Li L, Lan LY, Henry C, Stamper CT, McMahon M, O'Dell G, Fernández-Quintero ML, Freyn AW, Amanat F, Stovicek O, Gentles L, Richey ST, de la Peña AT, Rosado V, Dugan HL, Zheng NY, Tepora ME, Bitar DJ, Changrob S, Strohmeier S, Huang M, García-Sastre A, Liedl KR, Bloom JD, Nachbagauer R, Palese P, Krammer F, Coughlan L, Ward AB, Wilson PC. Nature 602 314-320 (2022)
  4. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth. Qiu Y, Stegalkina S, Zhang J, Boudanova E, Park A, Zhou Y, Prabakaran P, Pougatcheva S, Ustyugova IV, Vogel TU, Mundle ST, Oomen R, Delagrave S, Ross TM, Kleanthous H, Qiu H. J Virol 94 e01035-19 (2020)
  5. In silico structural homology modelling and docking for assessment of pandemic potential of a novel H7N9 influenza virus and its ability to be neutralized by existing anti-hemagglutinin antibodies. Rajapaksha H, Petrovsky N. PLoS One 9 e102618 (2014)
  6. PhosIDP: a web tool to visualize the location of phosphorylation sites in disordered regions. Nicolaou ST, Hebditch M, Jonathan OJ, Verma CS, Warwicker J. Sci Rep 11 9930 (2021)
  7. The Analysis of B-Cell Epitopes of Influenza Virus Hemagglutinin. Shcherbinin DN, Alekseeva SV, Shmarov MM, Smirnov YA, Naroditskiy BS, Gintsburg AL. Acta Naturae 8 13-20 (2016)
  8. research-article An explainable language model for antibody specificity prediction using curated influenza hemagglutinin antibodies. Wang Y, Lv H, Lei R, Yeung YH, Shen IR, Choi D, Teo QW, Tan TJC, Gopal AB, Chen X, Graham CS, Wu NC. bioRxiv 2023.09.11.557288 (2023)


Reviews citing this publication (45)

  1. Advances in the development of influenza virus vaccines. Krammer F, Palese P. Nat Rev Drug Discov 14 167-182 (2015)
  2. Continuing challenges in influenza. Webster RG, Govorkova EA. Ann N Y Acad Sci 1323 115-139 (2014)
  3. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. J Exp Med 213 469-481 (2016)
  4. Current and next generation influenza vaccines: Formulation and production strategies. Soema PC, Kompier R, Amorij JP, Kersten GF. Eur J Pharm Biopharm 94 251-263 (2015)
  5. From Original Antigenic Sin to the Universal Influenza Virus Vaccine. Henry C, Palm AE, Krammer F, Wilson PC. Trends Immunol 39 70-79 (2018)
  6. Universal influenza virus vaccines and therapeutic antibodies. Nachbagauer R, Krammer F. Clin Microbiol Infect 23 222-228 (2017)
  7. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Murin CD, Wilson IA, Ward AB. Nat Microbiol 4 734-747 (2019)
  8. Next-generation influenza vaccines: opportunities and challenges. Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Nat Rev Drug Discov 19 239-252 (2020)
  9. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A. Viruses 6 2735-2761 (2014)
  10. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Neu KE, Henry Dunand CJ, Wilson PC. Curr Opin Immunol 42 48-55 (2016)
  11. Novel universal influenza virus vaccine approaches. Krammer F. Curr Opin Virol 17 95-103 (2016)
  12. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Krammer F. Biotechnol J 10 690-701 (2015)
  13. Influenza Hemagglutinin Structures and Antibody Recognition. Wu NC, Wilson IA. Cold Spring Harb Perspect Med 10 a038778 (2020)
  14. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Sparrow E, Friede M, Sheikh M, Torvaldsen S, Newall AT. Vaccine 34 5442-5448 (2016)
  15. The Quest for a Truly Universal Influenza Vaccine. Jang YH, Seong BL. Front Cell Infect Microbiol 9 344 (2019)
  16. Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Wiersma LC, Rimmelzwaan GF, de Vries RD. Vaccines (Basel) 3 239-262 (2015)
  17. Options and obstacles for designing a universal influenza vaccine. Jang YH, Seong BL. Viruses 6 3159-3180 (2014)
  18. Stable long-term cultures of self-renewing B cells and their applications. Kwakkenbos MJ, van Helden PM, Beaumont T, Spits H. Immunol Rev 270 65-77 (2016)
  19. Influenza virus antigenicity and broadly neutralizing epitopes. Air GM. Curr Opin Virol 11 113-121 (2015)
  20. Structural Biology of Influenza Hemagglutinin: An Amaranthine Adventure. Wu NC, Wilson IA. Viruses 12 E1053 (2020)
  21. Prospects of HA-based universal influenza vaccine. Hashem AM. Biomed Res Int 2015 414637 (2015)
  22. Antibodies to combat viral infections: development strategies and progress. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Nat Rev Drug Discov 21 676-696 (2022)
  23. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Guthmiller JJ, Utset HA, Wilson PC. Viruses 13 965 (2021)
  24. Effector mechanisms of influenza-specific antibodies: neutralization and beyond. Sicca F, Neppelenbroek S, Huckriede A. Expert Rev Vaccines 17 785-795 (2018)
  25. Epitope-focused vaccine design against influenza A and B viruses. Ren H, Zhou P. Curr Opin Immunol 42 83-90 (2016)
  26. Immunogen design for HIV-1 and influenza. Rathore U, Kesavardhana S, Mallajosyula VV, Varadarajan R. Biochim Biophys Acta 1844 1891-1906 (2014)
  27. Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin. Nath Neerukonda S, Vassell R, Weiss CD. Vaccines (Basel) 8 E382 (2020)
  28. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus. Zhang Y, Xu C, Zhang H, Liu GD, Xue C, Cao Y. Viruses 11 E405 (2019)
  29. New Technologies for Influenza Vaccines. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. Microorganisms 8 E1745 (2020)
  30. T and B Cell Immune Responses to Influenza Viruses in Pigs. Holzer B, Martini V, Edmans M, Tchilian E. Front Immunol 10 98 (2019)
  31. Vaccines against influenza A viruses in poultry and swine: Status and future developments. Rahn J, Hoffmann D, Harder TC, Beer M. Vaccine 33 2414-2424 (2015)
  32. A Perspective on Nanoparticle Universal Influenza Vaccines. Deng L, Wang BZ. ACS Infect Dis 4 1656-1665 (2018)
  33. Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance. Mathew NR, Angeletti D. Front Immunol 10 2997 (2019)
  34. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Ringel O, Vieillard V, Debré P, Eichler J, Büning H, Dietrich U. Viruses 10 E197 (2018)
  35. From Variation of Influenza Viral Proteins to Vaccine Development. Zhu W, Wang C, Wang BZ. Int J Mol Sci 18 E1554 (2017)
  36. Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine. Tchilian E, Holzer B. Viruses 9 E98 (2017)
  37. Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines. Sangesland M, Lingwood D. Vaccines (Basel) 9 125 (2021)
  38. Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. Zambon M. Curr Opin Infect Dis 27 560-565 (2014)
  39. Next-Generation Influenza Vaccines. Kanekiyo M, Graham BS. Cold Spring Harb Perspect Med 11 a038448 (2021)
  40. Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. Wheatley AK, Kent SJ. Expert Rev Vaccines 14 1227-1239 (2015)
  41. Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses? Stadlbauer D, Nachbagauer R, Meade P, Krammer F. Front Med 11 471-479 (2017)
  42. A Complex Dance: Measuring the Multidimensional Worlds of Influenza Virus Evolution and Anti-Influenza Immune Responses. Wang J, Wiltse A, Zand MS. Pathogens 8 E238 (2019)
  43. Structural Insights for Anti-Influenza Vaccine Design. Han L, Chen C, Han X, Lin S, Ao X, Han X, Wang J, Ye H. Comput Struct Biotechnol J 17 475-483 (2019)
  44. Influenza virus glycoprotein-reactive human monoclonal antibodies. Li Y, Wang L, Si H, Yu Z, Tian S, Xiang R, Deng X, Liang R, Jiang S, Yu F. Microbes Infect 22 263-271 (2020)
  45. Recent advances in veterinary applications of structural vaccinology. Charleston B, Graham SP. Curr Opin Virol 29 33-38 (2018)

Articles citing this publication (71)

  1. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Nature 514 455-461 (2014)
  2. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kükrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radošević K. Science 349 1301-1306 (2015)
  3. Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ. Cell 166 596-608 (2016)
  4. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Henry Dunand CJ, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, Tan GS, Cruz J, Hirsh A, Zheng NY, Mullarkey CE, Ennis FA, Terajima M, Treanor JJ, Topham DJ, Subbarao K, Palese P, Krammer F, Wilson PC. Cell Host Microbe 19 800-813 (2016)
  5. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Bangaru S, Lang S, Schotsaert M, Vanderven HA, Zhu X, Kose N, Bombardi R, Finn JA, Kent SJ, Gilchuk P, Gilchuk I, Turner HL, García-Sastre A, Li S, Ward AB, Wilson IA, Crowe JE. Cell 177 1136-1152.e18 (2019)
  6. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D'ambrozio J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA. Cell Rep Med 2 100189 (2021)
  7. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. J Virol 88 13260-13268 (2014)
  8. The influenza virus hemagglutinin head evolves faster than the stalk domain. Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F. Sci Rep 8 10432 (2018)
  9. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, Ho IY, Taylor W, Hai R, Wrammert J, Ahmed R, García-Sastre A, Palese P, Krammer F, Wilson PC. J Clin Invest 125 1255-1268 (2015)
  10. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. J Virol 88 13580-13592 (2014)
  11. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Leon PE, He W, Mullarkey CE, Bailey MJ, Miller MS, Krammer F, Palese P, Tan GS. Proc Natl Acad Sci U S A 113 E5944-E5951 (2016)
  12. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. mBio 7 e01996-15 (2016)
  13. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Deng L, Mohan T, Chang TZ, Gonzalez GX, Wang Y, Kwon YM, Kang SM, Compans RW, Champion JA, Wang BZ. Nat Commun 9 359 (2018)
  14. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, Sui J, Fahmy A, Huang CY, Cadwell G, Bankston LA, McGuire AT, Stamatatos L, Wagner G, Liddington RC, Marasco WA. PLoS Pathog 10 e1004103 (2014)
  15. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Doud MB, Lee JM, Bloom JD. Nat Commun 9 1386 (2018)
  16. Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem. Lang S, Xie J, Zhu X, Wu NC, Lerner RA, Wilson IA. Cell Rep 20 2935-2943 (2017)
  17. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F. Vaccine 33 3314-3321 (2015)
  18. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice. Wohlbold TJ, Chromikova V, Tan GS, Meade P, Amanat F, Comella P, Hirsh A, Krammer F. J Virol 90 851-861 (2016)
  19. Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, Fouts A, Lupardus P, Wu TD, Li O, McBride J, Lawrence M, Xu M, Tan MW. PLoS Pathog 12 e1005702 (2016)
  20. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, Kolpe A, El Bakkouri K, Ysenbaert T, Deng L, Fiers W, Saelens X, Lycke N. Mucosal Immunol 11 273-289 (2018)
  21. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt JA, Albrecht RA, Vanderven HA, Bombardi R, Kent SJ, Ward AB, Wilson IA, Crowe JE. Nat Commun 9 2669 (2018)
  22. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. Wyrzucki A, Dreyfus C, Kohler I, Steck M, Wilson IA, Hangartner L. J Virol 88 7083-7092 (2014)
  23. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Tharakaraman K, Subramanian V, Cain D, Sasisekharan V, Sasisekharan R. Cell Host Microbe 15 644-651 (2014)
  24. HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids. Cox F, Kwaks T, Brandenburg B, Koldijk MH, Klaren V, Smal B, Korse HJ, Geelen E, Tettero L, Zuijdgeest D, Stoop EJ, Saeland E, Vogels R, Friesen RH, Koudstaal W, Goudsmit J. Front Immunol 7 399 (2016)
  25. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. Zost SJ, Wu NC, Hensley SE, Wilson IA. J Infect Dis 219 S38-S45 (2019)
  26. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, Witte MD, van Zoelen DJ, Cornelissen LA, Beaumont T, Bakker AQ, Ploegh HL, Spits H. Proc Natl Acad Sci U S A 111 16820-16825 (2014)
  27. A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y. EBioMedicine 17 182-191 (2017)
  28. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Wu NC, Thompson AJ, Lee JM, Su W, Arlian BM, Xie J, Lerner RA, Yen HL, Bloom JD, Wilson IA. Science 368 1335-1340 (2020)
  29. Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype. Mallajosyula VV, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA, Varadarajan R. Front Immunol 6 329 (2015)
  30. Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies. Bajic G, van der Poel CE, Kuraoka M, Schmidt AG, Carroll MC, Kelsoe G, Harrison SC. Sci Rep 9 3492 (2019)
  31. Intermolecular Interactions and Protein Dynamics by Solid-State NMR Spectroscopy. Lamley JM, Öster C, Stevens RA, Lewandowski JR. Angew Chem Int Ed Engl 54 15374-15378 (2015)
  32. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody. Prachanronarong KL, Canale AS, Liu P, Somasundaran M, Hou S, Poh YP, Han T, Zhu Q, Renzette N, Zeldovich KB, Kowalik TF, Kurt-Yilmaz N, Jensen JD, Bolon DNA, Marasco WA, Finberg RW, Schiffer CA, Wang JP. J Virol 93 e01639-18 (2019)
  33. Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. Sutton TC, Chakraborty S, Mallajosyula VVA, Lamirande EW, Ganti K, Bock KW, Moore IN, Varadarajan R, Subbarao K. NPJ Vaccines 2 35 (2017)
  34. Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P. J Virol 92 (2018)
  35. Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA. Cell Host Microbe 24 569-578.e4 (2018)
  36. Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses. Wang W, Sun X, Li Y, Su J, Ling Z, Zhang T, Wang F, Zhang H, Chen H, Ding J, Sun B. Nat Commun 7 13577 (2016)
  37. Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcγ receptor-activating antibodies. Demminger DE, Walz L, Dietert K, Hoffmann H, Planz O, Gruber AD, von Messling V, Wolff T. EMBO Mol Med 12 e10938 (2020)
  38. Design and Structure of an Engineered Disulfide-Stabilized Influenza Virus Hemagglutinin Trimer. Lee PS, Zhu X, Yu W, Wilson IA. J Virol 89 7417-7420 (2015)
  39. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13. Wohlbold TJ, Hirsh A, Krammer F. Vaccine 33 1102-1106 (2015)
  40. Anti-Hemagglutinin Antibody Derived Lead Peptides for Inhibitors of Influenza Virus Binding. Memczak H, Lauster D, Kar P, Di Lella S, Volkmer R, Knecht V, Herrmann A, Ehrentreich-Förster E, Bier FF, Stöcklein WF. PLoS One 11 e0159074 (2016)
  41. Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. Zost SJ, Dong J, Gilchuk IM, Gilchuk P, Thornburg NJ, Bangaru S, Kose N, Finn JA, Bombardi R, Soto C, Chen EC, Nargi RS, Sutton RE, Irving RP, Suryadevara N, Westover JB, Carnahan RH, Turner HL, Li S, Ward AB, Crowe JE. J Clin Invest 131 146791 (2021)
  42. In vivo dendritic cell targeting cellular vaccine induces CD4+ Tfh cell-dependent antibody against influenza virus. Yamasaki S, Shimizu K, Kometani K, Sakurai M, Kawamura M, Fujii SI. Sci Rep 6 35173 (2016)
  43. Recombinant influenza H9N2 virus with a substitution of H3 hemagglutinin transmembrane domain showed enhanced immunogenicity in mice and chicken. Zhang Y, Wei Y, Liu K, Huang M, Li R, Wang Y, Liu Q, Zheng J, Xue C, Cao Y. Sci Rep 7 17923 (2017)
  44. Unveiling a Drift Resistant Cryptotope within Marburgvirus Nucleoprotein Recognized by Llama Single-Domain Antibodies. Garza JA, Taylor AB, Sherwood LJ, Hart PJ, Hayhurst A. Front Immunol 8 1234 (2017)
  45. Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans. Aartse A, Eggink D, Claireaux M, van Leeuwen S, Mooij P, Bogers WM, Sanders RW, Koopman G, van Gils MJ. Vaccines (Basel) 9 717 (2021)
  46. Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies. Wang S, Ren H, Jiang W, Chen H, Hu H, Chen Z, Zhou P. J Virol 91 e02065-16 (2017)
  47. Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it. Wang W, Vassell R, Song HS, Chen Q, Keller PW, Verma S, Alvarado-Facundo E, Wan H, Schmeisser F, Meseda CA, Weir JP, Weiss CD. PLoS One 14 e0222436 (2019)
  48. Hemagglutinin Stalk Antibody Responses Following Trivalent Inactivated Influenza Vaccine Immunization of Pregnant Women and Association With Protection From Influenza Virus Illness. Dhar N, Kwatra G, Nunes MC, Cutland C, Izu A, Nachbagauer R, Krammer F, Madhi SA. Clin Infect Dis 71 1072-1079 (2020)
  49. Heterosubtypic cross-reactivity of HA1 antibodies to influenza A, with emphasis on nonhuman subtypes (H5N1, H7N7, H9N2). Te Beest DE, de Bruin E, Imholz S, Koopmans M, van Boven M. PLoS One 12 e0181093 (2017)
  50. Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model. Jang YH, Kim JY, Byun YH, Son A, Lee JY, Lee YJ, Chang J, Seong BL. Front Immunol 9 116 (2018)
  51. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies. Wang W, Song HS, Keller PW, Alvarado-Facundo E, Vassell R, Weiss CD. J Virol 92 e00247-18 (2018)
  52. Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses. McMillan CLD, Cheung STM, Modhiran N, Barnes J, Amarilla AA, Bielefeldt-Ohmann H, Lee LYY, Guilfoyle K, van Amerongen G, Stittelaar K, Jakob V, Lebas C, Reading P, Short KR, Young PR, Watterson D, Chappell KJ. NPJ Vaccines 6 135 (2021)
  53. Establishment of Systems to Enable Isolation of Porcine Monoclonal Antibodies Broadly Neutralizing the Porcine Reproductive and Respiratory Syndrome Virus. Goldeck D, Perry DM, Hayes JWP, Johnson LPM, Young JE, Roychoudhury P, McLuskey EL, Moffat K, Bakker AQ, Kwakkenbos MJ, Frossard JP, Rowland RRR, Murtaugh MP, Graham SP. Front Immunol 10 572 (2019)
  54. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. Yi KS, Choi JA, Kim P, Ryu DK, Yang E, Son D, Shin J, Park H, Lee S, Lee H, Im BH, Chae JS, Lee EB, Lee SY, Song M. PLoS One 15 e0236172 (2020)
  55. Influenza A HA's conserved epitopes and broadly neutralizing antibodies: a prediction method. Ren J, Ellis J, Li J. J Bioinform Comput Biol 12 1450023 (2014)
  56. A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies. Bailey MJ, Broecker F, Leon PE, Tan GS. J Vis Exp (2018)
  57. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. Moin SM, Boyington JC, Boyoglu-Barnum S, Gillespie RA, Cerutti G, Cheung CS, Cagigi A, Gallagher JR, Brand J, Prabhakaran M, Tsybovsky Y, Stephens T, Fisher BE, Creanga A, Ataca S, Rawi R, Corbett KS, Crank MC, Karlsson Hedestam GB, Gorman J, McDermott AB, Harris AK, Zhou T, Kwong PD, Shapiro L, Mascola JR, Graham BS, Kanekiyo M. Immunity 55 2405-2418.e7 (2022)
  58. Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses. Voronina DV, Shcheblyakov DV, Esmagambetov IB, Derkaev AA, Popova O, Shcherbinin DN. Acta Naturae 13 33-41 (2021)
  59. Enzyme Selectivity Fine-Tuned through Dynamic Control of a Loop. Vögeli B, Bibow S, Chi CN. Angew Chem Int Ed Engl 55 3096-3100 (2016)
  60. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. Yamayoshi S, Ito M, Uraki R, Sasaki T, Ikuta K, Kawaoka Y. J Infect 76 177-185 (2018)
  61. FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection. Ochsner SP, Li W, Rajendrakumar AM, Palaniyandi S, Acharya G, Liu X, Wang G, Krammer F, Shi M, Tuo W, Pauza CD, Zhu X. J Immunol 207 1310-1321 (2021)
  62. iBRAB: In silico based-designed broad-spectrum Fab against H1N1 influenza A virus. Do PC, Nguyen TH, Vo UHM, Le L. PLoS One 15 e0239112 (2020)
  63. Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus. Huang J, Huang N, Fan M, Zhao L, Luo Y, Ding P, Tian M, Liu Q, Guo Y, Zhao J, Zheng Y, Zhang H, Ping J. Virol J 17 191 (2020)
  64. Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin. Grødeland G, Baranowska-Hustad M, Abadejos J, Blane TR, Teijaro J, Nemazee D, Bogen B. Front Immunol 11 431 (2020)
  65. Neutralization and Binding Profile of Monoclonal Antibodies Generated Against Influenza A H1N1 Viruses. Shembekar N, Mallajosyula VV, Malik A, Saini A, Varadarajan R, Gupta SK. Monoclon Antib Immunodiagn Immunother 35 191-198 (2016)
  66. Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin. Finney J, Moseman AP, Kong S, Watanabe A, Song S, Walsh RM, Kuraoka M, Kotaki R, Moseman EA, McCarthy KR, Liao D, Liang X, Nie X, Lavidor O, Abbott R, Harrison SC, Kelsoe G. Proc Natl Acad Sci U S A 121 e2316964120 (2024)
  67. Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite. Cheung CS, Gorman J, Andrews SF, Rawi R, Reveiz M, Shen CH, Wang Y, Harris DR, Nazzari AF, Olia AS, Raab J, Teng IT, Verardi R, Wang S, Yang Y, Chuang GY, McDermott AB, Zhou T, Kwong PD. Structure 30 993-1003.e6 (2022)
  68. VarEPS-Influ:an risk evaluation system of occurred and virtual variations of influenza virus genomes. Shu C, Sun Q, Fan G, Peng K, Yu Z, Luo Y, Gao S, Ma J, Deng T, Hu S, Wu L. Nucleic Acids Res 52 D798-D807 (2024)
  69. Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity. Meade P, Strohmeier S, Bermúdez-González MC, García-Sastre A, Palese P, Simon V, Krammer F. J Virol 97 e0107022 (2023)
  70. Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes. Chen Y, Wang F, Yin L, Jiang H, Lu X, Bi Y, Zhang W, Shi Y, Burioni R, Tong Z, Song H, Qi J, Gao GF. Nat Commun 13 7603 (2022)
  71. Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice. Muralidharan A, Gravel C, Harris G, Hashem AM, Zhang W, Safronetz D, Van Domselaar G, Krammer F, Sauve S, Rosu-Myles M, Wang L, Chen W, Li X. Hum Vaccin Immunother 18 2083428 (2022)


Quick links